Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
Harvard Business School
McKesson
Colorcon

Last Updated: May 25, 2022

ENTEREG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Entereg patents expire, and what generic alternatives are available?

Entereg is a drug marketed by Cubist Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alvimopan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Entereg

A generic version of ENTEREG was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.

  Try it Free

Drug patent expirations by year for ENTEREG
Drug Prices for ENTEREG

See drug prices for ENTEREG

Recent Clinical Trials for ENTEREG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Cleveland ClinicPhase 4
Scott SteelePhase 4
Brigham and Women's HospitalPhase 3

See all ENTEREG clinical trials

Paragraph IV (Patent) Challenges for ENTEREG
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ENTEREG Capsules alvimopan 12 mg 021775 1 2017-06-16

US Patents and Regulatory Information for ENTEREG

ENTEREG is protected by one US patents.

Patents protecting ENTEREG

Methods of preventing and treating gastrointestinal dysfunction
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ENTEREG

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 See Plans and Pricing See Plans and Pricing
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 See Plans and Pricing See Plans and Pricing
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ENTEREG

See the table below for patents covering ENTEREG around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0506478 Dérivés de la pipéridine (Piperidine derivatives) See Plans and Pricing
China 1041309 See Plans and Pricing
Peru 41495 N-ALQUILCARBOXILATOS DE PIPERIDINILO 3,4,4-TRISUSTITUIDOS E INTERMEDIOS See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Mallinckrodt
Moodys
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.